Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional Universitaire (CHRU) in Tours, France, demonstrated that all of the asthma and COPD patients involved in the study, no matter how ill, were able to trigger the … [Read more...] about Study confirms ergonomic advantages of Aptar inhaler
News
Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology
Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of Drug Delivery, compared aerodynamic properties of PRINT-zanamivir inhalation powder to Relenza; the other, … [Read more...] about Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology
Pearl reports new data from studies of PT003
Pearl Therapeutics is presenting data from studies of its PT003 metered dose inhaler, glycopyrrolate (GP)/formoterol fumarate (FF) fixed dose combination for the treatment of moderate-to-severe COPD at a number of upcoming meetings. Pearl is also developing MDIs with each of the two component drugs, PT001 (GP) and PT005 (FF). According to the company, one of the … [Read more...] about Pearl reports new data from studies of PT003
Copley Scientific establishes distributors in Turkey, Brazil, and China
Inhaler testing equipment company Copley Scientific has entered into distribution agreements with companies in Turkey and Brazil and now has a Chinese sales and technical support representative in Nanjing, China. Copley sells a range of inhaler testing products, including impactors, delivered dose sampling apparatus, breath simulators, and proprietary inhaler testing … [Read more...] about Copley Scientific establishes distributors in Turkey, Brazil, and China
Pulmotect gets $7.1 million for inhaled immune system stimulant
Texas-based biotechnology company Pulmotect has been granted an award of $7.1 million by the Cancer Prevention & Research Institute of Texas (CPRIT) for development of its lead product PUL-042, an inhaled immune stimulant composed of two synthetic toll-like receptor agonists. The award is intended to fund preclinical, Phase 1, and Phase 2 studies of the product for … [Read more...] about Pulmotect gets $7.1 million for inhaled immune system stimulant
Study shows equivalent safety for Symbicort compared to budesonide alone in African Americans
AstraZeneca has announced results of a study showing that the safety profile of Symbicort budesonide/formoterol inhalation aerosol 320/9 µg twice daily was similar to that for a budesonide alone pMDI 320 µg twice daily in African-American patients with moderate-to-severe asthma. The data from the 52-week randomized, double-blind Phase IIIb safety study were published … [Read more...] about Study shows equivalent safety for Symbicort compared to budesonide alone in African Americans
AANMA announces winners of Innovations in Technology awards
The non-profit patient education organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) has announced the winners of its 2012 Top Ten Innovations in Technology Awards for "products and services that have meaningfully improved quality of life for people with allergies, asthma and related conditions." Of the ten winners, seven are OINDPs. AANMA Founder … [Read more...] about AANMA announces winners of Innovations in Technology awards
Melbourn Scientific adds Freeman Technology powder characterization capability
Melbourn Scientific is now offering powder characterization services using the Freeman Technology FT4 Powder Rheometer to optimize formulation and analysis services for inhaled drug and device development. Melbourn Scientific Operations Director Derek Solomon commented, “A key challenge of developing pharmaceuticals for inhalation is creating a formulation that … [Read more...] about Melbourn Scientific adds Freeman Technology powder characterization capability
Positive Phase 2 results for nasal spray to treat binge eating disorder
Lightlake Therapeutics has announced preliminary results from a Phase 2 trial of its intranasal naloxone for the treatment of patients with binge eating disorder. According to the company, the randomized, double-blind, placebo-controlled trial demonstrated that patients using the naloxone nasal spray spent a significantly smaller amount of time binge eating than did … [Read more...] about Positive Phase 2 results for nasal spray to treat binge eating disorder
Sunovion to launch Zetonna ciclesonide nasal aerosol in the US by Fall 2012
Sunovion has announced that it will make its Zetonna ciclesonide nasal aerosol for the treatment of allergic rhinitis available in the US in time for the fall allergy season. The FDA approved Zetonna, an HFA formulation delivered by nasal pMDI, in January 2012. Sunovion markets two other ciclesonide aerosols in the US: Omnaris nasal spray for the treatment of … [Read more...] about Sunovion to launch Zetonna ciclesonide nasal aerosol in the US by Fall 2012